期刊文献+

冠状动脉靶病变远端经微导管注射硝普钠对冠状动脉介入治疗中无复流的作用 被引量:9

Effects of nitroprusside injection from microcatheter to far-end target lesions on no-reflow phenomenon during percutaneous coronary intervention
下载PDF
导出
摘要 目的评价冠状动脉靶病变远端经微导管注射和直接冠状动脉内注射硝普钠对经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗中"无复流"的作用。方法选择PCI治疗中存在"无复流"现象的患者56例为研究对象,其中21例入选普通组,经指引导管冠状动脉内注射硝普钠200μg;23例入选改良组,经微导管注射硝普钠至靶病变远端;12例为对照组,经微导管注射0.9%氯化钠溶液至靶病变远端。10 min后复查冠状动脉造影,评定冠状动脉血流心肌梗死溶栓试验(thrombolysis in myocardial infarction,TIMI)分级及校正TIMI帧数(corrected tbrombolysis in myocardial infarction framecount,CTFC)。结果 3组均可改善PCI治疗后的"无复流"现象,普通组12例靶血管血流恢复TIMI 3级,CTFC帧数由用药前的(83.2±8.3)帧降至(38.1±7.5)帧;而改良组21例血流恢复TIMI 3级,CTFC帧数从(85.6±6.9)帧降至(27.3±6.8)帧;对照组1例血流恢复TIMI 3级,CTFC帧数从(84.3±7.4)帧降至(50.8±8.2)帧。改良组疗效明显优于普通组和对照组,差异有统计学意义(P<0.01)。结论 PCI治疗中,冠状动脉靶病变远端经微导管注射和经指引导管冠状动脉内注射硝普钠均能改善"无复流"现象,经微导管注射硝普钠至靶病变远端比经指引导管注射能更有效地改善PCI治疗中"无复流"现象。 Objectives To investigate the effects of nitroprusside injection from microcatheter to far-end target lesions on no-reflow phenomenon during percutaneous coronary intervention (PCI). Methods A total of 56 patients with no- reflow phenomenon during PCI were included in this study. Patients were divided into common group (nitroprusside 200 p^g injection from guiding catheter to target coronary,n =21), modified group (nitroprusside 200 p^g injection from microcatheter to far-end target lesions, n=23) and control group (physiological saline 5 mL injection from microcatheter to far-end target lesions,n=.12). Coronary angiography was rechecked 10 minutes after injection. Thrombolysis in myocardial infarction (TIMI) and corrected TIMI framecount (CTFC) of target coronary were assessed. Results Noreflow phenomenon relieved in all groups. There were 12,21, 1 patients with target coronary TIMI grade 3 in common group, modified group and control group respectively. CTFCs of target coronary were decreased from (85.6±6.9) frame to (27.3±6.8) frame in modified group, while those in common group reduced from (83.2±8.3) frame to (38.1±7.5) frame, those in control group reduced from (84.3±7.4) frame to (50.8±8.2) frame. TIMI and CTFC differences among the three groups had statistical significance (P〈0.01), the effects of modified group was the best. Conclusions Nitroprusside injection from guiding catheter and from microcatheter to far-end target lesions are effective and safe treatments for no-reflow phenomenon in PCI, and injection from microcatheter to far-end target lesions can achieve a better effect than from guiding catheter.
出处 《岭南心血管病杂志》 2012年第4期398-402,共5页 South China Journal of Cardiovascular Diseases
关键词 冠状动脉疾病 血管成形术 经腔 经皮冠状动脉 无复流现象 硝普钠 微导管 coronary artery disease angioplasty, transluminl, percutaneous coronary intervention no-reflow phenomenon nitroprusside microcatheter
  • 相关文献

参考文献12

  • 1ROMANO M, BUFFOL I F, LETYIERI C, et al. No reflow in patients undergoing primary angioplasty for acute myocardial infarction at high risk: incidence and predictive factors [J ]. Minerva Cardioangiol, 2005, 53( 1 ) : 7-14. 被引量:1
  • 2GIBSON C M, SCHOMIG A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusian [J ]. Circulation, 2004, 109 (25) : 3096- 3105. 被引量:1
  • 3ROMANO M, BUFFOLI F, TOMASI L, et al. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty : incidence, predictive factors, and long-term outcomes[J]. J Cardiovasc Mcd, 2008, 9(1): 59-63. 被引量:1
  • 4FALK E, THUESEN L. Pathology of coronary microembolisation and no reflow [ J ]. Heart, 2003, 89 (9) : 983 -985. 被引量:1
  • 5PIANA R N, PAIK G Y, MOSCUCCI M, et al. Incidence and treatment of ' no -reflow ' after percutaneous coronary intervention[J]. Circulation, 1994, 89(6) : 2514-2518. 被引量:1
  • 6WATANABE T, NANTO S, UEMATSU M, et al. Prediction of no-reflow phenomenon after successful percutaneous coronary intervention in patients with acute myocardial infarction: intravascular ultrasound findings [J]. Circ J, 2003, 67 (8) : 667-671. 被引量:1
  • 7GIBSON C M, CANNON C P, MURPHY S A, et al.Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction[J]. Circulation, 2002, 105(16) : 1909- 191. 被引量:1
  • 8STOEL M G, ZIJLSTRA F, VISSER C A. Frame count reserve [J]. Circulation, 2003, 107(24) : 3034-3039. 被引量:1
  • 9GIBSON C M, DOTANI M I, MURPHY S A, et al. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis [ J ]. Am Heart J, 2002, 144(1): 130-135. 被引量:1
  • 10VALERO S J, MORENO R, REYES R M, et al. Pharmacological approach of no-reflow phenomenon related with pereutaneous coronary interventions [J]. Cardiovasc Hematol Agents Med Chem, 2008, 6(2) : 125-129. 被引量:1

二级参考文献12

  • 1ROMANO M, BUFFOLI F, TOMASI L, et al. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes[J]. J Cardiovasc Med, 2008,9:59-63. 被引量:1
  • 2BROSH D, ASSALI A R, MAGER A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-monthmortality[J]. Am J Cardiol, 2007,99:442-445. 被引量:1
  • 3VALERO S J, MORENO R, REYES R M, et al. Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions[J]. Cardiovasc Hematol Agents Med Chem, 2008, 6: 125-129. 被引量:1
  • 4GIBSON C M, SCHOMIG A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion[J]. Circulation, 2004,109 : 3096-3105. 被引量:1
  • 5HILLEGASS W B, DEAN N A, LIAO L, et al. Treatment of no-reflow and impaired flow with the nit ric oxide donor nitroprusside follewing percutaneous coronary interventions., initial human clinical experience[J]. J Am Coll Cardiol,2001,37:1335-1343. 被引量:1
  • 6AIROLDI F, BRIGUORI C, CIANFLONE D, et al. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside[J]. Am J Cardiol, 2007, 99:916-920. 被引量:1
  • 7KLEIN L W, KERN M J, BERGER P, et al. Society of cardiac angiography and interventions: suggested management of the no-fellow phenomenon on the cardiac catheterization laboratory[J]. Catheter Cardiovasc Interv, 2003,60 : 194-201. 被引量:1
  • 8GIBSON C M, CANNON C P, MURPHY S A, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction[J]. Circulation, 2002,105 : 1909-1913. 被引量:1
  • 9STOEL M G, ZIJLSTRA F, VISSER C A. Frame count reserve [J]. Circulation, 2003, 107:3034 - 3039. 被引量:1
  • 10GIBSON C M, DOTANI M I, MURPHY S A, et al. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized efficacy study of tirofiban for outcomes and restenosis[J]. Am Heart J, 2002, 144:130-135. 被引量:1

共引文献4

同被引文献70

  • 1周滔,杨德光,陈小芳,肖孟,潜学勤.红细胞膜胆固醇水平与非ST抬高型急性冠状动脉综合征患者PCI相关冠状动脉慢血流或无复流发生相关[J].中国动脉硬化杂志,2015,23(4):379-383. 被引量:11
  • 2Rezkalla SH, Kloner RA. Coronary ncreflow phenomenon: from the experimental laboratory to the cardiac catheteriza- tion laboratory[J]. Catheter Cardiovase Interv, 2008,72 (7): 950-957. 被引量:1
  • 3Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans[J]. J Am Coll Cardiol, 2009,54(4) : 281-292. 被引量:1
  • 4Su Q,Li L,Liu YC. Short-term effect of verapamil on cor- onary no-reflow associated with percutaneous coronary in- tervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized con- trolled trials[J]. Clin Cardiol,2013,36(8) :E11-16. 被引量:1
  • 5Qin T, Xie L, Chen MH. Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-refiow phenomenon[J]. BMC Cardiovasc Disord, 2013,13 : 68. 被引量:1
  • 6Zhao SJ,Qi GX,Tian W, et al. Effect of intraeoronary ni- troprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analy- sis[J]. J Interv Cardiol, 2014,27 (4) : 356-364. 被引量:1
  • 7Gibson CM, Schemig A. Coronary and myocardial angiog- raphy: angiographic assessment of both epicardial and myocardial perfusion [J]. Circulation, 2004, 109 ( 25 ) : 3096-3105. 被引量:1
  • 8Salinas P, Jimene Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phe nomenon[J]. Cardiovasc Hematol Agents Med Chem, 2012,10(3): 256-264. 被引量:1
  • 9Heuseh G,Kleinbongard P ,BOse D, et al. Coronary micro- embolization:from bedside to bench and back to bedside [J]. Circulation,2009,120(18) : 1822-1836. 被引量:1
  • 10Niccoli G, Kharbanda RK, Crea F, et al. No-fellow: again prevention is better than treatment [J]. Eur Heart J, 2010,31(20) :2449-2455. 被引量:1

引证文献9

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部